The GPNMB knockout A-549 polyclonal cells constitute a human loss-of-function model generated via CRISPR/Cas9-mediated disruption of the GPNMB gene in A-549 lung carcinoma cells. This product is supplied as a polyclonal population, providing a heterogeneous knockout background suitable for studying GPNMB-dependent phenotypes in a relevant non-small cell lung cancer (NSCLC) context.
A-549 cells are a widely characterized alveolar basal epithelial cell line originally isolated from human lung adenocarcinoma tissue. These adherent epithelial cells serve as a standard in vitro model for NSCLC research, retaining key signaling features and oncogenic properties of lung adenocarcinomas.
GPNMB encodes a type I transmembrane glycoprotein (also known as osteoactivin or DC-HIL) that functions as a cell surface receptor and soluble ligand. It engages integrin receptors ??v??3 and ??v??5 and CD44 to activate downstream effectors including FAK, SRC, ERK1/2, and AKT, thereby promoting cell adhesion, migration, proliferation, and survival. Upstream regulators such as TGF-??, BMP2, EGF, and WNT ligands induce GPNMB expression, while its intracellular domain can be proteolytically released by ADAM10 to modulate ??-catenin transcriptional activity. GPNMB signaling is integrated with integrin-mediated adhesion, MAPK/ERK, PI3K/AKT, and WNT/??-catenin pathways, and interacts with matrix components like HSPG and SPARC.
In A-549 cells, endogenous GPNMB contributes to the malignant phenotype, including enhanced migratory and invasive capacity, modulation of MMP expression, and engagement with the tumor microenvironment. Disruption of GPNMB in this lung adenocarcinoma background offers a physiologically relevant platform to dissect its role in NSCLC progression, epithelial-to-mesenchymal transition, and signal transduction crosstalk. Because A-549 cells exhibit baseline activation of the PI3K/AKT and MAPK pathways, the knockout cells enable dissection of GPNMB-dependent versus -independent signaling events.
This knockout model is suitable for a broad range of functional studies, including tumor cell invasion/metastasis (via Transwell and cell adhesion assays), signaling pathway analysis (Western blotting for phospho-ERK1/2, phospho-AKT, and ??-catenin), gene expression profiling (RT-qPCR for downstream targets such as MMP-2 and VEGF), and investigation of immune regulatory roles (flow cytometry and co-immunoprecipitation). Researchers can employ these polyclonal knockout cells to explore mechanisms of drug resistance, angiogenic regulation, and the contribution of GPNMB to the lung cancer secretome. For further details, please contact Ascent Research.
